Results 181 to 190 of about 11,106 (236)
Some of the next articles are maybe not open access.
Ineffectiveness of Prophylactic Epsilon Aminocaproic Acid in Severe Hemophilia
New England Journal of Medicine, 1965SUBSTANTIAL advances have been made in recent years in the treatment of hemorrhage and management of surgical situations in hemophilia by replacement therapy employing plasma and various plasma fractions. Replacement therapy, however, is not suitable as a preventive measure because of its short-lived corrective effect and the risk of inhibitor ...
Sherwin V. Kevy +2 more
openaire +3 more sources
Unilateral essential hematuria therapy with epsilon aminocaproic acid
Urology, 1984A case of severe, unilateral essential hematuria was managed with epsilon aminocaproic acid. An extended remission of the hematuria was achieved with 24 Gm given orally in four divided doses daily, maintained for two weeks, then tapered by 2 Gm per day. The risks reported with this therapy are considered.
Anthony R. Henry, Daniel A. Nash
openaire +3 more sources
The influence of epsilon-aminocaproic acid on the mineralocorticoid hypertension of the rat
Experimental pathology, 1981The development of hypertension induced by DOCA/salt in rats can be reduced by epsilon-aminocaproic acid. Analogously to the clinical finding, glomerulopathy is also less marked. Recognising on the one hand the interaction between the coagulation system and the vessel wall and on the other hand the fibrinolysis-blocking properties of EACA, it can be ...
W. Bartsch +3 more
openaire +3 more sources
Pharmacokinetics of epsilon-aminocaproic acid during peritoneal dialysis
Journal of Neurosurgery, 1981✓ Two patients requiring peritoneal dialysis were treated with epsilon-aminocaproic acid (EACA), an antifibrinolytic agent. Samples of serum and dialysate were assayed for EACA concentrations. Total body clearance, dialysis clearance, EACA half-life, and volume of distribution of EACA were calculated.
Salvador Pancorbo +2 more
openaire +3 more sources
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid
Neurology, 1978Epsilon aminocaproic acid, an inhibitor of plasminogen and trypsinogen activators, can decrease the severity of experimental allergic encephalomyelitis (EAE) in rats. The drug was tried because of a number of observations suggesting that neutral proteases, such as plasmin, might be chemical mediators of demyelination.
James Kiernat +2 more
openaire +3 more sources
Epsilon‐aminocaproic acid myopathy
Australian and New Zealand Journal of Medicine, 1990K. Taylor, J. Randall
openaire +2 more sources
Diuretic Activity of Epsilon-Aminocaproic Acid
Pharmacology, 1968M.N. Mendes-Couto +2 more
openaire +3 more sources
Effects of Epsilon-Aminocaproic Acid on Fibrin Clot Lysis
Thrombosis and Haemostasis, 1966SummaryThe inhibitory effect of EACA on plasmin, urokinase, and SK-activator was investigated by means of fibrin clot lysis. Clot formation and resolution was followed by thrombelastography.Lysis of the simple fibrin clot by plasmin is inhibited by low concentrations of EACA. There is a dual effect of EACA on urokinase induced fibrinolysis.
openaire +3 more sources
EPSILON-AMINOCAPROIC ACID IN HÆMATURIA
The Lancet, 1975Ettore Degirolami +2 more
openaire +2 more sources